Soligenix Reports Clinical Success in Third Cohort of SGX302 Psoriasis Trial.

Soligenix announces extended results of its Phase 2a trial for SGX302 (synthetic hypericin) in mild-to-moderate psoriasis. Four additional patients were enrolled and treated with an optimized gel formulation, demonstrating clinical success. The gel formulation was designed to improve ease of application to larger skin areas. SGX302 was well tolerated with no drug-related adverse events.